Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Company Overview

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders and other conditions. Headquartered in Washington, D.C., the company was founded in 2003.

Its commercial products include Fanapt (iloperidone), approved in the United States for schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder, and Hetlioz (tasimelteon), used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome.

Vanda also develops investigational medicines, including tradipitant, which it has studied for conditions such as motion sickness and gastroparesis. Its commercial activities are centered on the U.S. market.

Key Stats

• Today's Range: $3.94 to $4.18
• 50-Day Range: $3.59 to $5.43
• 52-Week Range: $3.57 to $9.94
• Volume: 1.24 million shs
• Average Volume: 1.31 million shs
• Market Capitalization: $238.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Moderate Buy

Vanda Pharmaceuticals Stock Analysis - MarketRank™

Vanda Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 53rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vanda Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Vanda Pharmaceuticals has a consensus price target of $13.50, representing about 241.8% upside from its current price of $3.95.

Amount of Analyst Coverage

Vanda Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($2.53) to ($0.94) per share.

Price to Book Value per Share Ratio

Vanda Pharmaceuticals has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.12% of the float of Vanda Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 5.93.

Change versus previous month

Short interest in Vanda Pharmaceuticals has recently decreased by 8.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vanda Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vanda Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.73

News Sentiment

Vanda Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Vanda Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $38,069.00 in company stock, which represents 0.0159% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Vanda Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,069.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.70% of the stock of Vanda Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/28/2026
• Today: 11/12/2026
• Jefferies Global Healthcare Conference: 11/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VNDA
• CIK: 1347178
• Web: www.vandapharma.com
• Phone: (202) 734-3400
• Fax: 202-296-1450
• Employees: 533
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Vanda Pharmaceuticals: $13.50
• High Price Target: $20.00
• Low Price Target: $7.50
• Potential Upside/Downside: +241.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$220.47 million
• Net Margins: -119.87%
• Pretax Margin: -74.67%
• Return on Equity: -62.70%
• Return on Assets: -37.53%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.54
• Quick Ratio: 1.53

Sales & Book Value

• Annual Sales: $216.10 million
• Price / Sales: 1.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.31 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 60,470,000
• Free Float: 54,000,000
• Market Cap: $238.86 million
• Optionable: Optionable
• Beta: 0.74